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Abstract 
The emergence of new, effective therapeutic options has brought marked improvements 
in survival times and cure rates for many cancers. The cost of these advances, however, is 
staggering and has stretched thin the budget of the Centers for Medicare and Medicaid 
Services (CMS). In order to maintain its fiscal stability, CMS' s cost containment 
measures (e.g. the Medicare Modernization Act of 2003) have shifted cost to providers 
and health care consumers rather than restrict the availability of drugs or services. Such 
measures, however, fail to contain cost as they do not address the underlying etiology of 
soaring health care cost: unfettered access to exorbitantly priced drugs. 
I use the example of chemotherapy for colorectal cancer in the elderly to explore 
the cost of cancer care, and to demonstrate how current policies not only fail to contain 
cost, but also unintentionally increase the disparity between the wealthy who can afford 
optimal health care, and the average American senior who may be unable to afford state-
of-the-art cancer care. 
I propose that in our system with finite resources, we must accept that we cannot 
provide all possible care to everyone. If cost containment measures are to be successful 
and equitable, we must redefine quality care as excellent care for all, rather than all care 
for some. Cost-effectiveness, in addition to comparative clinical effectiveness, must 
become a focus of the drug approval process. Reforms such as the establishment of an 
Effectiveness Committee to review the clinical and cost-effectiveness of all new drugs, 
use of these data through a new "conditional" FDA approval system and incorporation of 
cost-effectiveness in CMS's reimbursement decisions, and a cost-sharing policy with the 
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pharmaceutical industry for drugs receiving only conditional approval by the FDA would 
begin to slow the growth in the cost of care. 
Although making cost-effectiveness a central consideration in drug approval and 
reimbursement decisions is likely to be unpopular, the American populace and its 
physicians are already quite dissatisfied with the extent to which they must shoulder the 
burden ofthe rising cost of medical care. Failure to act will only worsen this 
dissatisfaction, while allowing the growing divide between the care available to the 
wealthy and the care available to most Americans to widen. 
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Overview 
During his tenure as director of the National Cancer Institnte, cancer survivor 
Andrew von Eschenbach called for the elimination of "suffering and death from cancer 
by 20 15".1 With his call to arms, Dr von Eschenbach acknowledged that cancer research 
has advanced far enough that a future where cancer inflicts little suffering on the 
American people might be possible in our lifetime. Also implicit in his call to end cancer 
suffering and death is the notion that cancer care must be available equally to all cancer 
patients. In the current American health care system, however, these two notions are at 
odds, resulting in an expensive system that provides phenomenal care to some, and 
inadequate or no care to many. 
Modem chemotherapy is increasingly effective, lending support to the notion that 
we might meet Dr. von Eschenbach's goal. However, modem chemotherapy is also 
expensive. In the case of metastatic colo rectal cancer, median survival has quadrupled in 
the past decade from 6 to 9 months to upwards of 24 months with the availability of 4 
new classes of anti-cancer drugs.2 The cost of that therapy, however, has risen nearly 70 
fold, from $900 for six months of fluorouracil with leucovorin to $63,000 for six months 
of the most commonly used chemotherapy regimen--{)xaliplatin, fluorouracil, 
bevacizumab. These new drugs have been readily embraced by cancer patients and their 
physicians, who together strive to get the best possible treatment available for each 
individual cancer patient. With such a goal, little attention has been paid to the cost of the 
newly available drugs or to the ramifications of rising cost on the long term stability of 
the American health care system. Thus, though overall survival from cancer has 
improved to degree thought only a dream a few decades ago, without brakes on either the 
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price or the use of these new agents, the cost of cancer care has stretched thin the budgets 
of publicly funded insurers. 
These budget difficulties have put a system already plagued by disparities in 
health care delivery in further jeopardy, thus making it more difficult to reach the second 
portion of Dr. von Eschenbach's call: to provide care to all. Disparities in what cancer 
services are provided to racial/ethic minorities and the poor are already widespread in the 
U.S.3 In fact, though death rates from lung, breast, and colorectal cancers are declining, 
the disparity in cancer death rates between whites and racial and ethnic minorities is on 
the rise.4 With the high cost of modem cancer therapy, the Centers for Medicare and 
Medicaid Services (CMS) who provides care for the neediest of Americans, has begun to 
look for ways to pay for care; if the Medicare Prescription Drug, Improvement, and 
Modernization Act (MMA) of2003 is any indicator of future reforms, such cost-
containment measures will shift cost from CMS to physician practices through decreased 
reimbursement and to patients through increasing co-payments for services rather than 
addressing the underlying cause of increasing cost. As a result, those less advantaged will 
be even less likely to get cancer care. 
With continued focus on increasing the "ideal" therapy-the care that Dr. von 
Eschenbach believes may eliminate cancer suffering-and little attention to the plight of 
the publicly insured and the uninsured, it is likely that we may be able to eliminate 
suffering for wealthy Americans, while worsening the burden of cancer on those less 
fortunate. 
In these pages I will discuss why I believe that in order to diminish suffering from 
cancer, as a nation we must work together to redefine optimal quality health care. Rather 
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than valuing only care that maximizes anticancer benefit at a hefty price, we must also 
learn to value cancer therapies that, though perhaps slightly less effective, are priced to 
allow all Americans with cancer to have access to treatment. Using the case of colo rectal 
cancer in the elderly to illustrate my point, I will argue that our current policies and 
practice, predicated on the notion that we ought to provide ideal care to each individual, 
increase the use and cost of cancer therapy; because of a limited budget these practices 
are at odds with equitable health care delivery; past cost-containment efforts that 
maintain the ideal care paradigm, failed to control cost and risk worsening the equity of 
cancer care; and, future reform efforts ought to strive to achieve good care for all rather 
than ideal care for some. Finally, I will recommend that we begin this restructuring by 
reforming the manner in which we introduce novel anti-cancer therapies. 
Ideal care, the current goal of the American health system 
In her discussion of quality assessment, Gail Povar notes that the American health 
care system has generally adopted the notion that "ideal care"-meaning providing the 
best (most effective and least harmful) possible medical technologies for each 
individual-should be the standard by which we assess the quality of our health care. 5 In 
our system striving to achieve ideal care for the individual, the primary goal of health 
care practice and policy is implicitly defined a priori to be to provide every patient with 
each treatment that has any chance of benefit, regardless of cost. 
It is very important to note that Povar's argument that the highest quality of care is 
"ideal" care is not necessarily consonant with the Institute of Medicine's 1990 definition 
of quality of care as "the degree to which health services for individuals and populations 
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increases the likelihood of desired health outcomes and is consistent with current 
professional knowledge". The IOM definition of quality is elastic enough to include the 
possibility that "ideal" care- if that means "all possible care"- may not always, or even 
often, be a "desired health outcome" for the patient, or for society as a whole. The 
nuance inherent in this definition notwithstanding, the provider and patient communities, 
in practice, appear to endorse the principle of "ideal care." 
In the case of chemotherapy for cancer, this principle leads to our acceptance of 
exceedingly costly therapy for small, incremental improvements in cancer-free survival; 
to deny a patient such therapy, even if the incremental benefit over the standard of care 
option is small, would be to deny him or her the potential for a better cancer outcome, 
and thus would be in direct conflict with our a priori goal of maximizing care. 
As we shall see in our discussion of chemotherapy use in older colon cancer 
patients, using "ideal care" as a paradigm for policy and practice decisions ultimately 
results in worse care, on the whole, for American cancer patients as it may preclude many 
from receiving any therapy because of cost constraints, a notion certainly antithetical to 
our common understanding of equity and fairness in health care delivery. 
Rising costs of chemotherapy 
Advances in drug therapy have been the most prominent and productive recent 
achievements in cancer care. Because of our desire to incorporate any agent or treatment 
with some benefit, most of the recently approved drugs have been rapidly incorporated 
into the therapeutic armamentarium of routine clinical oncology practice. And while a 
few drugs clearly have changed the face of a particular cancer diagnosis, many produce 
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only small benefit, and a few are only non-inferior compared with the standard of care. 
The emerging field of molecularly targeted chemotherapeutics provides an number of 
illustrative examples of both our successes, drugs that may well be worth their price, and 
our failures, those drugs approved and used only because of our goal of providing each 
patient with ideal care at any cost. 
Molecularly targeted drugs are designed specifically to attack the cellular 
alterations that cause and propagate cancer. Because they target aberrant activity, these 
drugs largely spare normal tissue from toxicity; thus, they are highly regarded as more 
effective and less toxic than standard chemotherapies. However, the cost of their 
development is staggering. Such drugs are the result of years of laboratory research into 
the molecular biology of cancer, and subsequent years of clinical testing in animals and 
humans to prove safety and efficacy, making the cost of developing a new cancer drug 
around a billion dollars. 7 The pharmaceutical industry, that in combination with federal 
funding of basic laboratory research, foots the bill for drug development, has responded 
by marketing these agents at exorbitant prices: Bevacizumab (Avastin) is currently priced 
at approximately $100,000 for a year oftherapy.8 
Bevacizumab is also an example of a drug that is effective, but perhaps over used 
in our quest for ideal care. Bevacizumab, a monoclonal antibody directed against vascular 
endothelial growth factor, was approved for use in metastatic colorectal cancer in 
combination with fluorouracil after a phase III, randomized control trial showed it 
prolongs time to cancer progression (the time the patient can remain on chemotherapy 
before their cancer grows) by a median of 4 months and prolongs overall survival time by 
a median of 5 months (Table 1 ).9 Patients treated with bevacizumab were also more 
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Table 1, Benefit ofbevacizumab in metastatic CRC likely to have their cancer 
' 
shrink than those treated 
IFL IFL-bev FOLFOX FOLFOX-bev 
with chemotherapy alone, 
Median 15.1 mo 20.3 mo 19.9* mo 21.3* mo OS with response rates of 37% 
Median 6.8mo 10.6 mo 8.6mo 9.4mo TTP 
for chemotherapy and 45% 
-· 
""""" _____ 
-------
RR 37% 45% 50% 47% for chemotherapy plus 
IFL data from Hurwitz9, FOLFOX data from Saltz10• *OS combines FOLFOX and bevacizumab. At the time 
Cape/Ox arms, OS in FOLFOX subgroup not reported. Abbreviations: IFL, 
irinotecan, fluorouracil, leucovorin; bev, bevacizumab; FOLFOX, oxaliplatin, 
fluorouracil, leucovorin; OS, overall survival; TTP, time to progression; RR, this study was designed, 
response rate. 
the standard of care chemotherapy regimen was IFL (irinotecan, fluorouracil, leucovorin 
given by bolus infusion). Median survival in patients treated with IFL after their 
diagnosis of metastatic colo rectal cancer was only 15 months, making a 5 month 
improvement with bevacizumab a marked improvement and reason for excitement. Yet, 
in a subsequent randomized controlled trial in which patients treated with the 
chemotherapy regimen that replaced IFL as the standard of care, FOLFOX ( oxaliplatin 
with fluorouracil and leucovorin), were randomized to receive either bevacizumab or 
placebo, the benefit from bevacizumab was much smaller than in the prior study: a 0.8 
month improvement in progression free survival, and no improvement in response rate. 11 
Adding bevacizumab improved survival by 1.4 months compared with chemotherapy 
alone (Hazard ratio for death 0.89, 95% confidence interval 0.79-1.03), though the 
authors did not report on the benefit in the FOLFOX treated subgroup, rather they pooled 
patients treated with the standard of care (FOLFOX) with a newer, slightly less effective 
combination, the capecitabine/oxaliplatin regimen. Thus, with the current standard of 
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care chemotherapy regimen, bevacizumab adds approximately one month of time on 
chemotherapy before cancer progresses, and an average of one month survival. 
Given a price tag of approximately $100,000 per year, the cost-effectiveness of 
bevacizumab has been questioned, particularly in Europe. Even when assessing cost-
effectiveness ofbevacizumab compared with the inferior chemotherapy, IFL, the 
incremental cost-effectiveness is approximately £47,000 per year oflife gained and 
£63,000 per quality adjusted life year.12 These figures would be much higher if cost-
effectiveness were measured in comparison to the more effective chemotherapy, 
FOLFOX. Despite the newer evidence of only small benefit from bevacizumab, it 
continues to be used routinely in combination with FOLFOX as therapy of newly 
diagnosed metastatic colorectal cancer. 
Another drug in routine use with marginal benefit is erlotinib (Tarceva). Erlotinib 
is a small molecule inhibitor of the epidermal growth factor receptor (EGFR), a growth 
factor receptor that is overexpressed on many common cancer cells and is associated with 
poor prognosis. Erlotinib was approved for use in metastatic pancreas cancer in 
combination with the standard of care, gemcitabine, after a randomized control trial 
found a 0.3 month (5.9 months versus 6.2 months) improvement in survival in patients 
treated with gemcitabine-erlotinib compared with gemcitabine alone (Hazard ratio for 
death 0.82, 95% CI 0.69-0.99). Patients receiving the combination were also slightly 
more likely to be alive at one year, 23% versus 17%. 
An estimate of the cost of adding erlotinib to gemcitabine for metastatic pancreas 
cancer as done in this trial was estimated at approximately $15,200 per patient, with an 
incremental cost effectiveness of$410,000 per year of life saved and $430,000 per 
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quality adjusted life year. 13 Though, appropriately this approval was not met with as 
much enthusiasm as was the approval of bevacizumab, this was the first trial to 
demonstrate a statistically significant improvement in survival over gemcitabine alone 
after years offailed trials. Likely because of this distinction, erlotinib is used in clinical 
practice for metastatic pancreas cancer. 
Despite only marginal improvements offered by some drugs, others have 
drastically changed the prognosis of certain cancers. Imatinib (Gleevec) is one of these 
paradigm changing medications. Through its blockade of the Abelson tyrosine kinase, 
imatinib inhibits the underlying molecular abnormality that causes chronic myeloid 
leukemia (CML). With this oral drug, the vast majority of patients with newly diagnosed 
CML enter a prolonged remission. Imatinib is so effective that oncologists have had to 
rethink how to treat CML; in particular, the role of bone marrow transplantation--once 
the only hope for long term survival from this disease-is now uncertain. Imatinib does 
not come cheaply: one year's worth of therapy is estimated to cost approximately 
$30,000, 14 with an incremental cost effectiveness ratio compared to the prior standard of 
care of approximately $43,000 per quality adjusted life year. 15 
Clearly, drug discovery has led to considerable advances in cancer care, but these 
have come with a marked increase in the cost of oncology services. Even in the case of a 
disease changing drug, imatinib, cost-effectiveness is still near the upper bounds of what 
is often considered to be cost-effective. With health care consuming a record 
approximately 15% of the U.S. gross domestic product in 2002, an increasing proportion 
of which is shouldered by public payers, 16 the ability of the American health system to 
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continue to fund unabated growth-a growth fueled by our desire to give each individual 
ideal care-is not at all certain. 
Cancer in an aging population 
The population of the western world is aging. In the United States, the number of people 
over 65 will double by the year 2030, at which point one in five Americans will be over 
65. 17 As the incidence of all of the most common cancers (e.g. lung, breast, prostate, 
colorectal) increases markedly with age, in the absence of a substantial increase in our 
ability to prevent cancer, this population aging will bring an increase in the incidence and 
prevalence of the nation's second-leading cause of death--cancer-and an increase in the 
number of elderly cancer patients. By 2030 an estimated 70% of cancer patients will be 
over 65. 18' 19 
Recognizing that the face of the cancer patient is aging, most major cancer 
research organizations in the U.S. and Europe have developed geriatric oncology 
programs and research strategies to address better the needs of older cancer patients.20 
Thus far, research has focused on the extent of care currently offered to the older cancer 
patient and has largely found this care lacking. Notably, older patients are 
underrepresented in cancer clinical trials21 and are less likely than their younger peers to 
receive standard-of-care anticancer therapies such as chemotherapy or surgery?2• 23 These 
discrepancies in delivery of care between older and younger patients are perceived by 
many as underuse of effective therapy;24 and the underuse argument appears to have 
garnered strong support from oncology thought leaders in the U.S. At the 2007 annual 
meeting of the American Society of Clinical Oncology, a leading international society of 
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clinical cancer care, topics of geriatric oncology were more thoroughly represented than 
ever before?0 The prevailing sentiment of the conference favored an increase in the use 
of anticancer treatment, particularly chemotherapy, in older patients. 
Meanwhile, as we have already discussed, the pace and cost of new technology 
and drugs available to treat most common cancers has continued unabated. While I agree 
with the prevailing sentiment that age alone should not be a determining factor in the 
decision of whether or not to use chemotherapy,25 and that there is a likely a good deal of 
undertreatrnent of eligible older patients with cancer, it is critical that we discuss how 
routinely treating a greater proportion of elderly patients than we do at present will affect 
the cost of cancer care in the U.S. I do not propose that maintaining a policy of 
undertreating older patients ought to be a cost-containment measure, rather suggest that 
the current climate that moves to promulgate our ideal care paradigm in older patients 
will further stress publicly funded health care, and that if we do not address this problem 
now, the consequences are likely to worsen the care for many Americans. 
Colorectal cancer 
Colorectal cancer is the second leading cause of cancer death in the United States. 
An estimated 150,000 Americans are diagnosed each year, approximately 66% of whom 
are over the age of 65.4 At the time of diagnosis 39% have localized cancer, 36% have 
cancer spread to regional nodes, and 19% have metastatic disease.4 Thus, at least half of 
all patients diagnosed with colorectal cancer are eligible, based on stage alone, for 
chemotherapy treatment. The majority of these patients are elderly. 
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Adjuvant chemotherapy for colorectal cancer is effective. In localized or regional 
cancers, in which the cancer is confined to the colon or the lymph nodes surrounding the 
colon, primary therapy consists of surgical removal of the cancer. However, in stage II 
and III cancers relapse rates range from 20-80% depending on the extent of the primary 
tumor and the number oflymph nodes involved at the time of surgery. Chemotherapy 
given post-operatively as an adjunctive therapy decreases the relative risk of cancer 
recurrence by 30% with 6 months offluorouracil,26 or by an additional23% with 6 
months of fluorouracil with oxaliplatin26· 27 For example, a healthy 60 year old woman 
found to have a cancer invading through the wall of the colon and involving 6 lymph 
nodes has a 40% chance of being alive and cancer free at 5 years if treated with surgery 
alone. If given 6 months of adjuvant oxaliplatin and fluorouracil, her likelihood of 
disease-free survival at 5 years increases to approximately 70%. Given the small absolute 
reduction in the risk of cancer death afforded adjuvant therapy for stage II patients, 
estimated around 2-4%,28 chemotherapy is considered optional in patients with stage II 
cancers and is strongly recommended for stage III, node positive, cancers 
Chemotherapy in older patients with colorectal cancer 
Proponents of expanding the use of adjuvant chemotherapy to the majority of 
older colorectal cancer patients have a sound platform from which to argue. Despite 
concerns that the elderly may be at risk for greater chemotherapy toxicity, older 
colorectal cancer patients appear to derive the same benefit from chemotherapy as do 
their younger peers and suffer little increase in toxicity. In pooled analyses of elderly 
patients (>70) treated on large, phase III clinical trials of both single agent29 and 
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combination chemotherapy regimens30• 31 for colorectal cancer, older and younger 
patients have an essentially equal likelihood of being alive and cancer free at 5 years. 
Older patients do have a slightly increased risk of suffering a treatment-related decline in 
white blood cell counts from chemotherapy, 25 but this does not appear to translate into an 
increased risk of severe infection. 
Though older patients well enough to enroll on phase III clinical trials seemingly 
have little problem when treated in an identical fashion to younger patients, the majority 
of older patients diagnosed with stage II and III colon cancer are not as fit as those who 
have enrolled in clinical trials.25 Furthermore, older patients taking part in trials likely 
differ from those not on trials not just by a function of their health; they are more likely to 
be seen at a major medical center or community oncology group where research is a 
priority and physicians may be more up to date with recent literature. Clinical trial 
participants may also differ from patients treated outside of trials by socioeconomic 
factors such as education or income. As such, the excellent efficacy of chemotherapy in 
elderly colon cancer patients in the aforementioned pooled analyses is an inadequate 
measure of the effectiveness of treatment in the majority of older patients newly 
diagnosed with colon cancer. 
Colo rectal cancer researchers have made use of the Surveillance Epidemiology 
and End Results (SEER) database linked to Medicare claims to reduce the likelihood of 
selection bias in their comparisons of the outcomes of those receiving treatment to those 
not treated. Their hope is that SEER data will improve their estimates of the true 
effectiveness of adjuvant colon cancer therapy. SEER gathers data on incident cancers 
through selected US cancer registries, and currently represents approximately 25% of the 
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population.32 Approximately 93% of Medicare claims for persons over 65 have been 
matched to their SEER registry information/2• 33 and can be used to investigate surgery, 
radiation, and chemotherapeutics delivered to Medicare recipients. 
In 2002, two separate investigators used tbe SEER-Medicare linkage to ask if 
fluorouracil-based adjuvant chemotherapy improves mortality in older patients treated 
outside tbe venue of a clinical trial. 34• 35 Botb studies' investigators attempted to account 
for inherent differences between people who were treated with adjuvant therapy and 
those who were not by adjusting for factors known to be associated witb colon cancer 
outcomes using a propensity score. Both with and without adjustment by propensity 
score, older patients in the SEER-Medicare database who were treated with adjuvant 
fluorouracil had a lower chance of dying tban did those who did not receive adjuvant 
therapy. The 25-35% reduction in tbe risk of death seen in these investigations is similar 
in magnitude to the benefit of fluorouracil seen in clinical trials. 26 Preliminary data 
presented to date in abstract form only suggests that the effectiveness of combination 
chemotherapy in older patients may also be as robust in the community as in clinical 
trials.36 
In addition, despite tbeir advanced age, older patients with node positive colon 
cancer who forego chemotherapy are more likely to die of colorectal cancer than from 
other causes. Deborah Schrag and her colleagues from the Memorial Sloan Kettering 
Cancer Center noted that amongst Medicare recipients ages 75 to 84 witb stage III colon 
cancer, most of whom did not receive chemotherapy, colorectal cancer was by far the 
most common cause of death, suggesting that a number of these deaths may have been 
preventable with the use of adjuvant therapy22 
16 
Sanoff, HK 
Chemotherapy use declines with age 
Despite its efficacy, chemotherapy use declines with patient age. 22• 37-42 In 1995, 
five years after a National Institutes of Health consensus conference declared adjuvant 
chemotherapy the standard of care for colorectal cancer with lymph node involvement,43 
fewer than one half of patients 75-79 and fewer than a quarter of patients over 80 
received adjuvant therapy41 In comparison, 78% of patients under 55 were treated with 
adjuvant chemotherapy for their cancer41 By 2000, this trend was largely unchanged, 
suggesting that diffusion of information about adjuvant therapy effectiveness did not 
underlie the lack of use in the elderly42 
Ideal care in a non-ideal system: how costly care impairs equitable delivery 
There can be little doubt that more elderly patients with stage III colon cancer, given our 
current health care goal of providing ideal care to each individual, should receive 
chemotherapy. Indeed, given the apparent tolerability and benefit of adjuvant 
chemotherapy in the elderly, it is hard to argue that expanding chemotherapy use might 
not improve colorectal cancer outcomes for many elderly cancer patients who currently 
go untreated. However, when considering how to maximize the quality of care in the 
elderly, we must also address how promulgating increasingly costly care for a growing 
segment of our population will affect the delivery of cancer care. 
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Reducing conflict over, and inequality in, delivery of cancer care 
A rigorous application of standards of "justice" in cancer care delivery requires 
the elucidation of four points: that we do, in fact, have a positive right to health care; that 
the positive right includes such advanced and costly care as cancer therapy; that "justice" 
requires treating relevantly similar interests the same; and that "other things are equal," 
between patients -that is, that the reasons different patients may be treated differently are 
not reasons that affect whether their interest in treatment is relevantly similar. 
Without asserting that justice, in these terms, requires equality of care, we can, 
nonetheless, make specific claims about particular inequalities in treatment, and the 
growing conflict these inequalities engender between professional commitments to 
patient care- the focus on "doing everything" for a given patient- and caring for whole 
communities or populations of patients. 
We have already seen that the cost of cancer care has been rising, fueled by new 
discoveries in molecularly targeted agents and our desire to provide ideal care. Using the 
case of adjuvant therapy of the elderly with stage III colon cancer we shall now 
investigate a practical example of the extent to which our desire to optimize each 
individual person's care may be financially untenable for CMS, and why it puts justice in 
cancer care at greater risk. 
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Cost of adjuvant chemotherapy for colon cancer 
As with all cancer care, largely because of the emergence of new drugs, the cost 
of colorectal cancer chemotherapy has risen rapidly in the past decade. Until the mid-
1990s fluorouracil, still the backbone of colorectal cancer therapy, was the only available 
drug. In the fluorouracil era, chemotherapy treated patients with metastatic colorectai 
cancer could expect to live approximately 12 months compared with 6-9 months without 
treatment.44 Similarly, patients treated with adjuvant fluorouracil could expect a 20-30% 
reduction in their risk of colorectal cancer recurrence after surgery.26 
In 1996, the modern era of chemotherapy was ushered in with the FDA approval 
of irinotecan for use in metastatic disease. Approval of capecitabine (1998), oxaliplatin 
(2002), bevacizumab (2004 ), cetuximab (2004 ), and most recently panitumumab (2007) 
rapidly followed. With the arrival ofthis modern chemotherapy era, the outlook for many 
colorectal cancer patients has markedly improved. The median survival for patients with 
metastatic disease is now upwards of 2 years, 2 and by adding oxaliplatin to fluorouracil 
as adjuvant therapy the risk of cancer recurrence falls by another 25%.27 
The advent of these new therapies has clearly decreased morbidity and mortality 
from colorectal cancer; however, their cost is astounding. In the example scenario we 
have been discussing of 6 months of adjuvant therapy for stage II or III colon cancer, 
drug costs alone for the most commonly used regimen (FOLFOX) are around $36,000 
(Table 2).45 This figure does not include the cost of nursing services, routine supportive 
medicines such as anti-emetics, red or white cell growth factors, or the time costs for 
patients and their family. 
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Table 2, Estimated Cost of Various Chemotherapy Regimens 
DRUG COST TOTAL COST for ELDERLY* 
Regimen 8 weeks 6 months Treating 55% Treating 75% 
. 
.. ·. #Bolus FU/LV $304 $912 $21· million $29million 
lnfusional FUlL V $263 $789 $ 18 million $25 million 
I FOLFOX ·. 
. ·· .. · .. . .·. 
$11,889 ! $35,667 I $823million $1.12billion 
FOLFOX/bev $21,033 $ 63,009 $1.46 billion $1.98 billion 
.· 
. . .· 
FOLFOX/cetux $33,183 $99,5~9 ·. $2.23 billion $3.14 billion 
. . 
FOLFOX!bev/cetux $42,327 $126,981 $2.93 billion $4.00 billion 
Drug costs based on 95% of average wholesale price in 5/2004 from Schrag.45 * 
Assuming 150,000 new CRC cases/year, 70% pts >65, 40% with high risk stage II or 
stage 11I disease. # Most commonly used regimen before 2004. FOLFOX/bev/cetux 
and FOLFOX/cetux are not FDA approved combinations. Abbreviations: NA, not used 
for adjuvant therapy; FU, fluorouracil; LV, leucovorin; FOLFOX, 
fluorouracil/leucovorin/ oxaliplatin; bev, bevacizumab; cetux, cetuximab. 
Furthermore, the cost of adjuvant therapy will likely rise. Ongoing phase III 
cancer cooperative group clinical trials incorporate the biologic agents bevacizurnab and 
cetuximab into adjuvant therapy with FOLFOX. The results of the first of these trials is 
expected in the summer of2009, and if any finds a statistically significant difference in 
disease-free survival at 3 years, the combination regimens ofFOLFOX-bevacizumab or 
FOLFOX-cetuximab will likely become a routine part of adjuvant colorectal cancer 
therapy in the United States. If so, drug costs alone for 6 months of adjuvant therapy 
would fall between $60,000 and $120,000 per patient. 
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Cost of expanding chemotherapy use in the elderly 
Of the 150,000 colorectal cancers diagnosed each year, 70% occur in people over 
the age of 65. As at least 40% of these patients have lymph node positive or high risk 
lymph node negative colon cancer, approximately 42,000 people over the age of 65 are 
eligible for adjuvant therapy each year.4 We currently treat approximately 55% of those 
over 65 with adjuvant therapy.22 Advocates of expanding chemotherapy use in to more 
older patients suggest increasing the proportion treated and increasing the proportion 
treated with FOLFOX, the more aggressive and more effective regimen. Currently, of 
those treated with adjuvant therapy the majority are likely treated with fluorouracil, so the 
cost of adjuvant therapy is currently between 21 (if all receive fluorouracil) to 800 
million dollars (if all receive FOLFOX)-likely closer to 21 than 800 million. If we were 
to increase chemotherapy use such that 7 5% of older patients were treated with 
FOLFOX, the armual cost would increase to just over 1 billion dollars. If we were to 
incorporate cetuximab into adjuvant therapy the cost would increase to 3.1 billion dollars 
per year. Thus, expanding therapy as advocated to use more FOLFOX in more older 
patients might increase the cost of drug fees alone by nearly a billion dollars a year to 
ensure ideal care for 42,000 people. 
Rising costs and failed justice 
An ideal medical system would perhaps not flinch at the thought of spending an 
additional billion dollars per year to decrease the risk of colon cancer recurrence in 
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42,000 older patients. Such a system would have no limits to spending, allowing the 
goals of providing optimally beneficial care and providing care to all to coexist as 
rational goals for the health care system. Unfortunately, however, no health care system 
has unlimited funds. As Milton Weinstein of Harvard University explains, the only 
alternatives in a system with limited funds are compromises, "either with the principle of 
universal access, or with the principle of unlimited care. "46[ P268l In America, we have 
been unwilling to compromise our access to unlimited care, as demonstrated perhaps best 
by the case of the approval of erolotinib for metatstatic pancreas cancer at approximately 
$15,000 for an average of 10 days prolongation oflife. In the treatment of older cancer 
patients, funded largely by CMS, our desire for unlimited care has forced us to 
compromise in our ability to provide care to as many cancer patients as we would like. 
Responses to rising cost of cancer care: MMA 
It was in this setting of rising cancer cost, with an increasing public contribution 
to overall health care spending, 16 that the Medicare Prescription Drug, Improvement, and 
Modernization Act was passed in 2003. As a means of cost containment, the MMA 
targeted the cost of cancer drugs reimbursed by Medicare Part B by enacting a marked 
revision of the payment schedule for Part B drugs, the vast majority of which are 
delivered to cancer patients. 
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MMA changes in chemotherapy reimbursement 
Before 2004, Medicare reimbursed for chemotherapy (and all Part B eligible 
drugs) at 95% of each drug's annual wholesale price (A WP). The A WP was calculated 
from prices listed by vendors for chemotherapy; however, as chemotherapy providers 
(e.g. hospitals and outpatient physician practices) negotiate purchase price with vendors, 
just as a new car's sticker price is almost never the price agreed upon by the dealer and 
the new owner, the A WP is not reflective of the actual transaction price. Rather, by 
negotiating and buying drugs at prices substantially below A WP, chemotherapy providers 
made substantial profit from the purchase and subsequent delivery of Medicare 
reimbursed Part B drugs. 
This profit margin allowed oncology practices to flourish financially. Not only did 
the profit afforded by the A WP reimbursement formula cover high salaries for many 
practicing oncologists, but it also allowed oncology practices to cover the cost of drug 
delivery by specialty trained oncology registered nurses and the administrative costs of 
the practice. The A WP-generated profit also allowed community oncology practices to 
treat at a loss a proportion of uninsured and nnderinsured patients nnable to meet their 
high copayments without putting the practice at undue financial risk.47 
In 2004 all of that changed. The MMA called for a transition from paying A WP to 
a new formula in which drugs are reimbursed at their average sales price (ASP) plus 6%. 
The ASP is calculated from the actual average transaction cost between vendors and 
providers in the prior two quarters. The MMA reform allowed for a two year transition: 
Drugs were reimbursed at 85% of A WP plus 32% in 2004, at 106% of ASP plus an 
additional3% in 2005, and by 2006 reimbursement reached the MMA goal of 106% of 
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ASP .48 The MMA also created a competitive acquisition program (CAP) in 2006. In the 
CAP, physician groups would be allowed to opt into a program where all drugs were to 
be supplied by Medicare. Medicare would purchase drugs from vendors by accepting the 
lowest bids, and then supply them directly to providers' offices. Payments would them go 
directly to vendors from Medicare, and patients would be billed the copay by the vendor. 
However, presumably given the low level of reimbursement expected from Medicare, no 
bids were offered from vendors and this program has been temporarily put on hold.49 
To offset the MMA mandated decrease in drug payments, chemotherapy 
providers were asked to bill for chemotherapy delivery services according to the amount 
of work performed (e.g. intravenous push of chemotherapy or an hour long infusion). No 
provision was made to cover the indirect costs of patient care. 
A major goal of chemotherapy reimbursement reform in the MMA was to contain 
costs by correcting what was seen as an overpayment for chemotherapy services. At the 
time of MMA enactment the Medicare Payment Advisory Commission (MedP AC) was 
directed to provide Congress with reports on how the MMA had influenced cost and 
services. In the MedPAC January 2006 and 2007 reports, the Commission noted that 
despite increasing use of oncology services, reimbursement for drugs under Part B drug 
remained largely unchanged in 2005 and 2006.49· 50 
Consequences of MMA reimbursement reform 
Though effective in containing costs for CMS, the MMA drew criticism from the 
media, physicians, and patient groups because of perceived financial risks to oncology 
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practices and the Medicare beneficiary with cancer47 Of particular concern was the fate 
of small, often rural, oncology practices that were perceived as less able to withstand 
financial pressure imposed by reduced drug reimbursement. The patient and physician 
groups were also concerned about the fate ofunderinsured Medicare beneficiaries who 
might now be expected to come up with 20% copays for astronomically expensive 
treatments. 
Burden of MMA on the outpatient oncology clinic 
Critics of the MMA argued that its reimbursement reform places a significant 
financial burden on oncology providers likely to result in changes in how practices are 
managed and how care is delivered. In 2003, 80% of chemotherapy infusions took place 
in outpatient physician offices.49.51 Under the new reimbursement rules, however, 
Medicare drug payments might no longer cover the cost of chemotherapy delivery in the 
outpatient office setting. In particular, though drugs and nursing care are theoretically 
reimbursed in full, there is no provision for indirect cost or unpaid bills. 
Though it is too early fully to assess how changes in reimbursement truly affect 
the financial viability of office-based oncology practices, there does already appear to be 
reason for concern. In their 2006 report to Congress, MedPAC reported the results of 
interviews with physicians in all regions of the U.S. Physicians and office managers 
reported that since the institution of MMA reimbursement reform they have spent more 
time and resources on the acquisition of drugs, in some cases hiring specific purchasing 
personnel. Financial constraints have forced some practices to cut benefits for staff, 
substitute part-time for full-time employees, and to replace trained oncology nurses with 
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pharmacy technicians to save money. Most frightening, perhaps, was the admission of 
some physicians that the reform caused them to choose patients based on their ability to 
49 pay. 
If, as the MedP AC report suggests, under the new Medicare payment structure 
outpatient oncology practices cannot cover direct and indirect costs of chemotherapy 
delivery, they will have to find a way to shift the financial burden elsewhere or eventually 
close. In particular, practices will need to make a decision about how to handle money-
losing cases such as chemotherapy regimens where the cost of delivering care is greater 
than Medicare reimbursement and cases where Medicare beneficiaries are unable to meet 
their 20% copay. There are two clear options in such cases: treat in a hospital-based 
setting or do not treat. 
By shifting delivery of chemotherapy either to a hospital run outpatient clinic or 
an inpatient chemotherapy ward, oncology practices transfer the cost of indirect 
chemotherapy services such as drug purchasing, billing, and other administrative duties 
to the hospital. In addition, because Medicare reimburses hospitals for up to 70% of 
copays not met by Medicare beneficiaries, hospital infusion clinics run a much lower 
financial risk when treating Medicare patients responsible for 20% copays.49 Because 
most physicians are affiliated with hospitals already, shifting care to hospitals would not 
change the continuity of most physician-patient relationships. 
The potential financial consequences of reimbursement reform are perhaps 
greatest in small oncology practices and rural clinics. Small practices have always been 
less able to negotiate with vendors for low drug prices, yet they previously earned enough 
from the A WP reimbursement formula to overcome this disadvantage. In the new model, 
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reimbursed at ASP + 6%, small practices without negotiating power will be less able to 
get drugs for below the ASP. Since the ASP is calculated from actual transaction prices 
from the previous quarters, the ability of larger practices to negotiate a lower price drives 
the ASP down, further hurting the small practices. This already appears to be the case: 
the 2006 MedPAC report found small practices were unable to purchase 15% of the most 
commonly used drugs at or below ASP. The MedPAC report of2006 also noted that a 
number of larger practices have been able to supplement their income by adding 
diagnostic capabilities to their practice (e.g. positron emission tomography scanners); 
smaller practices do not have the capital to undertake such costly expansion.49 
Thus, the MMA reimbursement reforms clearly put pressure on oncology 
practices. Such pressure may well lead to a shift in the site of cancer care to hospital-
based settings, and is most likely to affect the financial stability of smaller practices. 
The cost to the disadvantaged Medicare beneficiary 
Though the MMA reimbursement reform will strain the financial stability of 
outpatient oncology practices, the majority oflarge practices will likely be able to 
restructure their practice in a way that allows them to continue to function in a fashion 
quite similar to the pre-MMA era. Similarly, patients with private insurance or Medicare 
with supplemental insurance living within reasonable proximity of a large oncology 
practice will likely notice few differences in their cancer care. Unfortunately, however, 
poor Medicare recipients without supplemental insurance and small practices, often 
located in rural areas, are likely to feel the sting of the MMA reform. Thus, it is the poor 
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and the rural-dwelling cancer patients who are likely to be affected adversely by the 
MMA. 
Rural communities tend to be served largely by small practices or rural satellite 
clinics operated by large practices in neighboring towns. As the MMA squeezes both 
small and large practices they will be forced to restructure their spending. For large 
practices operating satellite clinics at a loss for the community, an early cost-cutting 
maneuver may be to do away with the money loosing satellite. Small practices will feel 
the financial pressures most and may be forced to turn away patients unable to pay or be 
forced to operate at a loss-a prospect that carmot go on forever. Whether small practices 
and satellites close or simply turn-away poor patients, either option would leave the rural 
communities they serve without adequate cancer care. 
In addition, it is the poorest of Medicare patients who are most likely to suffer if 
outpatient practices transfer chemotherapy delivery to hospital-based settings when 
reimbursement fails to meet the practice's cost. Hospital-based services are both more 
expensive and less efficient than outpatient oncology clinics. Thus, the out-of-pocket 
expenses for Medicare beneficiaries will increase if they are shunted to hospital-based 
clinics. In addition, shifting the patient's infusion to the hospital run clinic will mean 
many clinical and administrative services will be duplicated, such as blood draws and 
vital signs, thereby increasing the practical time burden on patients.49 Because of their 
inability to meet copays, it is the poorest Medicare patients who are mostly likely to be 
referred to hospital-based infusion clinics. Thus, the patients who already have worse 
cancer outcomes-the poor and the rural dwelling-are most likely to be harmed by the 
new financial pressures of the MMA reimbursement reforms. 
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Will these fears be realized? 
Though the new payment structure clearly favors large practices and the referral 
of patients without supplemental insurance to hospital clinics, it is not yet clear if these 
forecasted changes in practice pattern will truly happen. 
In 2005 the National Patient Advocate Foundation contracted the Duke University 
Center for Clinical and Genetic Economics to investigate whether there had been any 
change in the site of chemotherapy administration, the time until chemotherapy initiation, 
or the patient perceived ease of referral from 2003 (pre-MMA) to 2004. Using Medicare 
claims data, the Duke study found no differences in the site of care or the length of time 
until treatment was initiated. 51 In addition, an internet survey of self-selected cancer 
patients found no difference in the perceived ease of referrals for or receipt of 
chemotherapy between 2003 and 2004. A subgroup analysis showed a hint that rural 
patients and patients without supplemental insurance were more likely to be treated at a 
hospital-based clinic, however the numbers of such patients were too small to allow for 
adjustment for potential confounding factors such as comorbidity. 
As noted by its authors, the Duke study was probably conducted too early truly to 
assess MMA-related change in chemotherapy practice. Even though drug reimbursements 
fell in 2004 they were still substantially above the reform's target. In addition, payments 
to oncology practices from the Medicare Quality of Life Demonstration Project served to 
cushion the blow of falling reimbursement. The Demonstration Project, initiated 
concurrently with the MMA reforms, paid participating oncology practices $130 per 
patient per visit to ask Medicare patients three questions about fatigue, nausea, and pain. 
Thus, combined with reimbursement at A WP + 32%, participating practices still brought 
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in a substantial sum of money for treating Medicare patients in 2004. Furthermore, 
though well intentioned, the Duke internet survey respondents were self-selected 
oncology patients motivated and savvy enough to find and respond to a survey about their 
care. Their responses are not likely representative of the majority of Medicare 
beneficiaries. 
The 2006 and 2007 MedP AC reports, however, are more alarming. Both years 
the Commission reported that, as predicted, small oncology practices were more likely to 
affected by the reimbursement reform.49• 50 The Commission also reported that compared 
to Medicare beneficiaries with supplemental insurance, those without supplemental 
insurance were more likely to receive chemotherapy in a hospital-based inpatient or 
outpatient setting. Though the commission found no evidence that the quality of cancer 
care was diminished by the MMA mandated reimbursement reforms, they readily 
acknowledged that measures of quality are complex, and they were not equipped 
adequately to address that question. 
Though MedP AC reports to Congress from March and June of 2008 do not focus 
on the consequences of the MMA on cancer therapy, they both stress a serious concern 
about Medicare's long-term sustainability in the setting of rising costs and an increasing 
number of baby boomers almost ready to enroll in Medicare. The March 2008 report 
notes that viability will require both a reduction of expenditures and new financing, 52 
neither of which has been enacted with the exception of decreasing reimbursement. This 
report also notes that with the current trajectory, the burden of cost sharing borne by 
patients will increase; though beneficiaries are likely to continue contributing a stable 12-
13% of the program's revenue through premiums and copays, this will make up an 
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increasingly large proportion of beneficiaries' income as costs rise and social security 
does not. The nearly 50% of Medicare beneficiaries with yearly incomes less than 
$20,000 dollars are most likely to feel the sting of this cost sharing. 
Cost-containment: moving toward a more equitable policy paradigm 
We have seen that current policy efforts have focused on controlling cost to the 
payer by shifting cost to physicians, hospitals, and cancer patients. None, however, have 
directly addressed the underlying cause of increasing cost: with our gold standard for 
quality being ideal care for each individual, we are unwilling to deny any patient a drug 
that provides even marginal anti-cancer benefit. If this continues to be our goal, and we 
fail to act now in a proactive fashion, CMS will be forced to mal<e difficult decisions 
about reimbursement. Without the political will to deny the most costly treatments, 
CMS's only means of cutting cost will again be to shift it towards another party. This 
path seems to lead us to a system of cancer care in which costly ideal care, improving all 
the time with new discoveries and drugs, will be available to those Medicare patients able 
to afford supplemental insurance or high copays, while many-particularly the 
disadvantaged-receive suboptimal or no care at all. The time for action is now, as these 
negative effects of rising cost have already begun to jeopardize American health care. 
Indeed, the 2007 report of the Medicare Board of Trustees concludes that financial issues 
resulting from the rising cost of care demonstrate the "need for timely and effective 
action to address Medicare's financial challenges". 53 
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I believe the best way to address this rising cost and the resultant rising imbalance 
in cancer treatment is collectively to re-evaluate the framework from which we have 
made decisions about American health care. Our current goal-to provide ideal cancer 
care to each individual--can only be just if resources are unlimited. In such a case, each 
older colorectal cancer patient could receive 6 months ofFOLFOX at $36,000, or 6 
months ofFOLFOX-bevacizumab at $63,000 without drawing resources from another 
cancer patient. However, it is patently clear that resources in our health care system are 
not unlimited. Thus, the only way for us to provide care that is just is for us to re-define 
quality care as that care which is optimal for all, 5 accepting that many may receive care 
that is no longer "ideal." In such a scenario we may be willing to treat all patients with 
FOLFOX, but decide that we are unwilling to pay $30,000 more for the marginal benefit 
afforded by the addition ofbevacizumab. 
We will only be successful in redefining our notion of quality therapy if we can 
gamer the collective will to do so.46 Without the backing of physicians, those who 
ultimately chose which therapy to administer, many might continue to strive for ideal 
care for each of their own patients, leaving other, unseen patients with less care. 
Similarly, patients as consumers must be willing to accept that justice in health care 
ought to be one of our guiding principles, and that they may have to sacrifice their 
unlimited access to care so that all cancer patients can receive good treatment. And 
though the notion of sacrifice has become distinctly un-American, now is the time for 
that to change. 
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Building patient support 
Such collective acceptance of a need tore-frame the goals of our health care 
system will be difficult, as for decades the notion of entitlement to the best available care 
has become an American way of life. Even patients without effective treatment options 
clearly want more care. In a survey of patients enrolling in phase I oncology trials (in 
which the trial goal is to assess the safety of the new agent without any expectation on 
the part of the investigators of clinical efficacy), only 7% had seriously considered 
getting no additional cancer treatment despite having received many prior lines of therapy 
for incurable disease. 54 Furthermore, 90% of these phase I trial enrollees reported they 
would be willing to accept a 10% risk of death for access to the experimental drug. These 
figures are despite the fact that the likelihood a patient will benefit personally from 
enrollment is quite small: approximately 4% experience reduction in cancer size when 
participating in a phase I trial of a new chemotherapy. 55 Even at the end of life, many 
American cancer patients seem to prefer receiving more anticancer therapy, even with a 
marginal benefit and substantial risk. 
But, patients have already begun to feel the untoward effects of rising costs. 
Americans currently pay approximately 13% of their medical costs out of pocket, 56 a 
proportion that represents a larger and large absolute value as costs rise. In addition, 
premiums for private insurance for a family increased 73% from 2000 to 2005, compared 
with an inflation rate of 14% during the same time period. 56 The strain of these costs 
appears to be affecting Americans' ability to access good care. In 2006 survey, 43% of 
Americans living with a cancer patient reported having to choose suboptimal care (e.g. 
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skipping treatment, cutting pills, or not filling a prescription) because of cost. 57 This 
difficulty paying for needed care extended to all Americans, not just those with cancer: 
23% of Americans reported having a difficult time paying their medical bills, 61% of 
whom were insured. In a Kaiser Foundation Daily Health Report from July 8'h, 2008, 
noted bioethicist Arthur Caplan of the University of Pennsylvania is quoted as saying that 
the high cost of cancer drugs is "one of the toughest issues in oncology" as high drug 
prices can mean trading "family assets for a few more months oflife".58 
The rising cost of prescription drugs is a main contributor to the cost burden of 
medical care on families. Recently, the high prescription drug cost has led 86% of 
Medicare part D providers and 10% of private insurers to decrease their benefits for 
expensive prescription drugs through the creation of a "Tier 4" payment scheme. 59 Drugs 
selected for inclusion in Tier 4 are covered, but the patient must pay typically between 
20-33% of the cost-a figure that may be in the hundreds of dollars per month. A New 
York Times article about this change notes that insurers claim this new system allows 
them to keep premiums down for healthy subscribers by shifting the cost of these 
extremely high price drugs to the sick emollees59 The article highlights the effect of this 
Tier 4 scheme on patients with severe or life-threatening chronic illnesses such as 
multiple sclerosis, chronic myeloid leukemia, and metastatic breast cancer. The 
individuals interviewed for the article stress how this new payment system has forced 
them to chose between paying for their medicines and paying for other crucial life events, 
such as their children's education. 
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As a result of these difficulties, 86% of Americans believe that the US health care 
system needs to be fundamentally changed or to be completely rebuilt. 57 And despite 
arguments against a national health plan that might require rationing or limits in choice as 
do the Canadian and British systems, three times the number of Americans are 
dissatisfied with the health care system as are Canadian and British citizens. 57 Seventy 
percent of Americans also believe that the US government should be paying more for 
health care, 57 signaling Americans may well be open to more government involvement in 
how our health care system operates. 
Thus, though Americans continue to want ideal care--even want care from which 
they have an exceedingly small chance of benefiting-all but the wealthiest of Americans 
have been affected by the rising price of American health care; and, importantly, most 
Americans recognize that a fundamental change in the structure of our health care system 
is needed. As such, with the right support, the American people could likely be 
encouraged to reconsider the paradigm from which our health care decisions are made. 
Securing physician support 
Just as many cancer patients report wanting to receive treatments that offer even 
the smallest hope, their physicians want to be able to offer them such treatments without 
regard to the implications of the treatment decision outside the confines of what is best 
for that patient. Though American physicians are not unique in their desire to provide the 
best possible care for their patients, those practicing in many other countries have been 
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able to work successfully from a framework where providing care is more important than 
providing ideal care for the individual. 
Perhaps as a result of inherent differences in the underlying goals of our health 
care systems, the oncology treatment culture in the U.K. is much different than our own, 
exemplified in the conduct and interpretation of a recently completed phase III trial in 
metastatic colorectal cancer. The FOCUS trial was conducted in the U.K. in the late 
1990s through the early 2000s.60 In this trial the sequential use of single agent 
chemotherapy drugs (fluorouracil or irinotecan) was compared to the upfront use of 
combinations of irinotecan, oxaliplatin, and fluorouracil. Median survival for the patients 
treated with single agent therapy was approximately 14 months, while those treated with 
initial combination chemotherapy survived an average of 16 months. The British authors 
concluded that survival was not improved by the more aggressive therapy, and they have 
continued to conduct studies that include single agent arms. On the other hand, American 
oncologists largely used this trial to argue in favor of combination therapy as the standard 
of care,2 and American cooperative oncology groups no longer conduct trials of single 
arm therapies. Certainly, both groups are correct to some degree: from the standpoint of 
advancing research, combination therapies are likely the best platform from which to 
build. However, single agent therapy should be an accepted treatment option for all 
patients with metastatic colorectal cancer, and may be a less costly way to get cancer care 
to all Americans. 
Clearly, less costly and slightly less effective treatment options are available for 
routine clinical use; yet, a physician's primary obligation is to their patient.46· 61 
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Confronted with the choices offered by the FOCUS trial, of whether to offer a 69 year old 
otherwise healthy woman with stage IV colon cancer the less effective and cheaper 
fluorouracil or the more effective and more costly FOLFOX, a physician should not have 
to consider how giving FOLFOX to this patient will diminish Medicare's coffers. Rather, 
the physician should discuss the options with the patient and make the correct decision 
for that patient. Unfortunately, cost has become an issue in the routine practice of 
oncology. In a survey of practicing oncologists, 42% report routinely discussing 
chemotherapy cost with patients. 62 Yet, placing such decisions in the exam rooms erodes 
the essence of the doctor patient relationship.61 Similarly, cost-containment measures that 
seek to use differential reimbursement as an incentive for physicians to select cheaper 
care force the physician to chose between society and the individual ill, vulnerable patient 
who sits before them.46 We should not rely on the doctor to be the gatekeeper of change; 
rather, change should be directed by a national understanding of our need to contain costs 
and be mandated at the level of national policy. 
Physician support of change, however, will be essential if any real change is to 
take place in how care is delivered in the US. Just as patients have to pay more as a result 
of the rising cost of American medicine, physicians have also felt the sting of decreased 
Medicare reimbursement, suggesting they may be open to supporting policy change. In a 
survey of 8,955 physicians conducted by the American Medical Association regarding 
the effect of the 5% cut in Medicare reimbursement recommended for 2008, 45% of 
responding physicians reported they would be forced to either decrease or entirely stop 
accepting new Medicare patients.63 Furthermore, 72% said they would be forced to defer 
the purchase of new medical equipment, and 67% would defer the purchase of new 
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information technology (a clear concern given the importance of information technologic 
in decreasing errors and generally improving the quality of medical care). 
Given that the cost of delivering medical care is not likely to fall in the near 
future, declining reimbursement in the setting of rising costs will continue to place 
physicians in a financially difficult position, perhaps opening them to the thought of 
redefining optimal quality care. 
Perceptions of the medical elite 
In order to assess the climate within the academic medical community with regard to cost 
and cost containment measures for cancer therapies, I conducted a systematic review of 
the medical literature. I search PUBMED using the following terms: cost; cost-
effectiveness; cancer; chemotherapy. The search was limited to English language articles 
published between January 1, 1990 and June 30, 2008. In addition, the search was limited 
to clinical trials and editorials. I chose to include editorials in this search because a main 
goal was to assess the climate for change amongst the academic oncology community. As 
opinions and conjecture are most likely to be included in discussion sections and 
editorials, these were the primary sites of the search. This search yielded 291 potentially 
eligible articles. Abstract review narrowed this field to 17 articles possibly meeting the 
entry criteria of: discussing cancer chemotherapy and cost AND discussing solutions, 
policy, or opinion regarding cost management. Eleven articles64• 74 met the eligibility 
criteria and are included in the review. 
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A major theme of the reviewed papers was the notion that health care resources 
are finite. As such, deciding to accept a new drug or treatment for use in clinical practice, 
even if deemed relatively cost-effective, requires shifting resources from another 
service-perhaps from other health care services, or possibly from other societal services 
such as infrastructure or education. In their commentary on the cost of trastuzumab for 
breast cancer therapy, Drs. Hillner and Smith of the Massey Cancer Center note that the 
US drug approval and reimbursement system has generated a perfect storm of cost 
increases: patients want access to new drugs and technology and meanwhile are relatively 
protected from the cost of these new therapies by only having to pay co-payments; the 
FDA does not negotiate drug prices with manufacturers; and Medicare does not consider 
cost in reimbursement decisions. 64 And, because of this increasing cost, without action to 
increase the pool of resources, such as dramatically increasing taxes, clinical use of even 
extremely effective drugs such as trastuzumab means diverting funds from another 
service. Such divergence of funds is also noted by Drs. Ramsey and Kessler, principally 
the decline in physician reimbursement by Medicare72 Drs. Elit, Gafni, and Levine of 
McMaster University in Ontario further note that within a fixed budget, it is best to look 
to cut inefficiencies within the same system-in their case the treatment of cervical 
cancer-rather than to divert resources from distant sources.74 
The American medical elite were in agreement that there should be a greater, 
more transparent national discussion of the cost of cancer treatment. Hillner and Smith 
believe that cost-effectiveness must be taken into greater account in decision-making 
about the availability of cancer therapies,64 and Ramsey and Kessler call for an open 
dialogue about the cost of care. 72 Ramsey and Kessler go on to say that the medical elite, 
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namely the National Cancer Institute funded Cancer Cooperative groups that serve as the 
thought leaders of cancer therapy, should both include cost-effectiveness analyses as part 
of clinical trials and consider cost when making decisions about what drugs to include in 
future clinical trials as these trials ultimately dictate what drugs will be used in routine 
clinical practice.72 In their commentary on the editorial by Ramsey and Kessler, Roberts, 
Lynch and Chabner concur that the cost of care is high, but strongly caution against any 
incorporation of cost into direct patient treatment decision-making, noting that such 
considerations are antithetical to physicians' ethics.73 They do agree, it seems, that a 
"macro-level" discussion about cost would be appropriate, but that in the US there is no 
real venue in which to have this discussion as there is no central health system to guide 
decisions and no guiding principles are available to help incorporate ethics and individual 
preferences into health economic decisions. Perhaps because of these short-falls, they 
title their commentary, "Choosing chemotherapy for lung cancer based on cost: not 
yet"73 
Bartley Madden, an "independent researcher" from Napervilje, Illinois, proposes 
more specific means of containing cost. In his commentary he notes that one of the main 
drivers of the high cost of pharmaceuticals is the FDA approval process that requires 
complex and costly clinical trials to demonstrate efficacy and safety; this process drives 
up the cost of drug approval to the drug developer, and is eventually borne by the 
consumer.71 He proposes a trial of a new dual tracking system for FDA approval, in 
which drugs may follow the traditional pipeline through FDA approval, or may chose to 
go through a process that allows for greater freedom of choice. This freedom of choice 
track would permit patients and physicians to purchase from a distributor drugs that have 
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passed phase I trials without any significant concern for safety. Though minimal or no 
efficacy data would be available on these drugs, Madden argues patients and physicians 
are capable of understanding that notion: those unwilling to take the risk would not make 
use of this track, while those with fatal diseases for which no treatments are available-
he uses the example of Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)-would 
have access to potentially beneficial medications. Madden argues that this process would 
speed drug discovery as a larger number of patients with a variety of ailments would be 
exposed to the drug and data on their outcomes would be a requirement of participation. 
He also argues that this dual tracking method would serve as a feedback mechanism for 
the current FDA process-pointing out where inefficiencies and waste are common. 
In contrast to the American comments that focused largely on the unregulated cost 
of cancer care, comments from the other, largely British, authors focused on criticisms of 
the cost-containment measures already in place. These criticisms are largely 
representative of frustration in the ability to gain access to drugs, with comments focused 
on the UK's National Institute for Health and Clinical Excellence (NICE). In response to 
an article by Jonnson and Wilking about the uptake of new cancer drug therapy that noted 
drug uptake in the UK was among the slowest, that criticized NICE as the cause of this 
slow uptake, and further noted cancer mortality in the UK is among the highest in 
Europe, 75 the editorial staff of the Lancet noted that the UK needs to decide on a national 
plan to achieve better survival and more quality adjusted life years. They note that if cost 
is the only issue being considered, then the system is failing. 67 
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NICE is further criticized in two commentaries about the approval process of 
bortezomib (Velcade ), a proteasome inhibitor approved in the US for use in relapsed or 
refractory multiple myeloma. Despite bortezomib's superior ability to induce a clinical 
response and prolong time to tumor progression and overall survival compared with the 
standard of care in this uniformly fatal disease, it was not recommended by NICE for use 
in the UK based on the cost of the drug and the modest benefit it offers over other 
conventional therapies. As a result of public outcry, NICE's decision was altered in June 
of2007, allowing use ofbortezomib in the second-line treatment of multiple myeloma by 
way of a cost-sharing plan with the UK distributor, Janssen-Cilag. According to this 
agreement, the drug was allowed for 4 months. If the patient did not respond, the 
company reimbursed the National Health Service (NHS) for drug costs. These decisions, 
both the original rejection and subsequent limited approval, raised a number of important 
concerns about NICE's approval process. Eric Low, the Chief Executive of Myeloma 
UK, noted that the current mechanism for drug approval through NICE often does not 
result in a "fair or sensible treatment availability", as was the case in the bortezomib 
decision.69 In particular, he criticizes the arbitrariness of the QAL Y and the pre-set cost-
limits that do not allow for fair consideration of a costly drug for a disease such as 
myeloma with a short life expectancy. The concept that the current cost-effectiveness as 
inappropriate for drugs used in terminal illness was echoed in the discussion of a cost-
effectiveness analysis of cetuximab as third line treatment for colorectal cancer in which 
the authors note with a short survival the absolute benefit of a drug will always be small, 
driving up the cost -effectiveness ratios; they argue in the case of terminal illness with 
short survival, higher cost should be allowed.70 Low concludes by suggesting greater 
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transparency in the review process, and an open discussion about means for reform. Also 
in response to the bortezomib decisions, the editorial staff of Lancet Oncology suggested 
that rather than using rebate schemes to allow for limited approval of drugs, NICE should 
look into lowering the cost of drugs by better regulating the pharmaceutical industry. 
They acknowledge, however, that the US is likely the only country with a large enough 
market share to negotiate lower drug prices. 66 
The high cost of cancer care has clearly sparked a degree of unrest amongst the 
academic elite in both the US and the UK. In the US, academic oncologists have only 
begun the discussion--calling for a national consideration of cost, rather than a specific 
change. In the UK, the discussion focuses on reforming a cost-containment system to be 
more responsive to the needs of patients than the need to manage cost. While clearly 
neither American nor European academic oncologists have presented a comprehensive 
plan for cost-containment that both lowers cost while maintaining a goal of providing 
excellent cancer care, many are clearly ready for change. Their support as thought-leaders 
of the future of cancer care will be paramount to any successful plan to change our 
outlook on how to deliver care. 
Recommendations for reform 
No single solution will halt the staggering growth in the cost of medical care in 
the US. A combination of reforms that tackle inefficiency and waste in addition to the 
cost of new technology will certainly be needed if we hope to curtail the current projected 
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growth that predicts Medicare spending will be 9% of the gross domestic product by 
2050.52 However, as I hope I conveyed, our national desire to provide ideal care to each 
and every patient has hampered reform efforts to date, resulting in measures that require 
patients and physicians to shoulder a greater burden of this cost without addressing its 
cause. 
I believe a critical component to successful cost containment is the establishment 
of an independent body to review the comparative clinical effectiveness and cost-
effectiveness of new drugs and technologies, and to make recommendations about drug 
approval to the FDA and reimbursement to CMS based on their findings. Such a body 
would provide invaluable evidence to support approval and reimbursement decisions by 
the FDA and CMS, and, if done well, could also be a launching point for opening a true 
national dialogue on our national goals for health-ideal individual care or equitably 
delivered excellent care for all. 
In addition to opening a discussion about cost through this committee, the FDA 
and CMS must begin to place greater weight on the cost-effectiveness of their approvals 
and reimbursement decisions, as I fear the best of intentions of the intellectual elite will 
be insufficient to bring about real change. 
Establishment of an independent Effectiveness Committee 
I believe an important next step in major reform for our health care system is the 
establishment of an independent committee commissioned to assess the clinical and cost 
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effectiveness of therapies. This Effectiveness Committee would be charged with 
evaluating new drugs and technologies prior to FDA approval, and providing evidence of 
comparative effectiveness for already established therapies (see Table 3). 
Effectiveness Committee models 
In proposing a structure for the Effectiveness Committee, I believe we should take 
into account the model of the UK's NICE, and incorporate changes to overcome some of 
the aforementioned criticisms. MedP AC has also suggested the establishment of a similar 
committee, and I believe most of their recommendations should be adopted. 
NICE serves as an excellent model upon which to base our committee. NICE's 
primary functions are to provide guidance on the promotion of health and the prevention 
of illness, to evaluate and provide guidance on the use of new treatments by the National 
Health Service, and to provide guidance on the appropriate treatment and care of people 
with disease.76 Through its Centre for Health Technology Evaluation, NICE conducts 
appraisals of new drugs and devices with regard to both their clinical effectiveness and 
their cost-effectiveness. Recommendations are then provided to the NHS about coverage. 
The NHS is legally required to fund any medication or technology that is recommended 
by a NICE appraisal. 
Establishment of a committee to evaluate comparative clinical effectiveness was 
also recommended by the Medicare Payment Advisory Committee in 2007 and again in 
the June 2008 report.77 MedPAC recommended the establishment of an independent 
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committee funded by federal and private monies to review the comparative clinical 
effectiveness of new and already accepted treatments. This committee would conduct 
appraisals transparently, and provide their results to interested parties (payers, providers, 
and patients). Importantly, MedPAC recommended that the committee have no role in 
making or recommending coverage or payment decisions based on the results of their 
studies. In addition, MedP AC specified that the committee could conduct cost-
effectiveness research if so desired, but that this should not be the primary aim of the 
committee. 
Proposed Effectiveness Committee structure 
First, the Committee should be composed of largely of academic researchers with 
expertise in cost-effectiveness and comparative effectiveness research; it should also, 
however, include representatives of all aspects of health care such as representatives of 
payers (CMS and private insurers), practicing physicians, and patient advocates. These 
health system representatives should be included as a second task of the committee will 
be to educate, research and report upon the American public's will for accepting cost as 
part of drug approval process. As is the practice with NICE, commissions about given 
technology or drugs would be distributed to contracting teams from academic centers 
able to conduct rapid assessments. The results of the assessments would be provided to 
the FDA, CMS, and published in peer-reviewed journals as well as a Committee website. 
Secondly, the committee should be charge with two main objectives: 
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• Generating comparative clinical and cost effectiveness research on new drugs and 
devices undergoing consideration of FDA approval, and existing drugs with high cost 
and concerns of marginal benefit. 
• Garnering political will for cost-based decision-making in US health care with the 
American public and conducting research on public will. 
The June, 2008 MedP AC report recommended that the effectiveness committee focus on 
conducting comparative clinical effectiveness research only, with cost-effectiveness 
research playing a minimal role only if desired by the committee. I strongly disagree with 
this soft approach to the conduct of cost-effectiveness research. I believe that should be a 
primary charter of the committee; providing clinicians with evidence of comparative 
effectiveness alone may improve the efficiency of resource utilization, but it will not 
provide adequate information to truly curtail the rising cost of our system. Thus, real 
cost-based decisions on the availability of drugs will be necessary and the FDA and CMS 
will need reliable cost-effectiveness data upon which to base decisions. 
I do, however, agree with the MedP AC recommendation that the Committee 
should not have power over funding decisions based upon their findings. Criticisms of 
NICE can teach us that too much power in such a committee is detrimental to its public 
acceptance.67· 69• 75 The Committee's role in drug approval and funding decisions should 
be to provide independent, high quality evidence upon which other players can make 
sound policy decisions. 
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Table 3, Proposed reforms for curtaining growth in drug and technology costs 
Structure of Reform I Key Points 
; ''·'·' 
... 
·' . . Coriiiriilteeori'Clinici!l and'Cost~E:f'fectiveness .. ,·. .;· .. , ••. ···' · .... , .. · · · ··· .. · ·.·.·., > ··•· •. :.· •• •· 
Independent organization Public and private funding reduces obligation to 
serve one party. 
Transparency in conduct Reduce criticisms of decisions 
Comprised of research experts with advocates from -Upholds primary aim of conducting research 
payers, physicians, patients - Includes voices from interested parties 
Not responsible for approval or reimbursement - Keeps decision-making separate from research 
decisions - Minimizes questions of bias 
Conduct town meetings to inform public - Initially open dialogue with frequent meetings 
throughout US 
- Subsequent meetings twice a year to continue 
dialogue 
. :: ... ,·. ,, .:·· ····.· "'·''•. ····· ,; >Centers for Medicare.ancl Medicaid Ser¥ices •·· ·: ... ,,···· 
.· 
. , .... ; 
Mandated to include cost in consideration of -Use committee's assessments 
reimbursement -No preset cut-offs of cost-effectiveness 
Mandated to negotiate drug prices - Huge market share should drive down cost 
1:;·:.,,,,, .. ·,. /·>·:···.,···· ·''· FOod andDruli;'A.dril.iriistration ·')'··;·,·· .··.'·.··.·,·· ·.·· ·.· ... . .·.• ....... , ., ; 
Mandated to include cost in consideration of -Use committee's assessments 
reimbursement -No preset cut-offs of cost-effectiveness 
Allow for conditional approval with cost-sharing - Drugs with marginal effectiveness can be 
approved. 
-Tight post-marketing surveillance on 
safety/efficacy 
-Cost-sharing with manufacturer if ineffective 
I also agree with the MedP AC recommendation for a committee funded through both 
public and private funds. A lesson that might be learned from the aforementioned criticisms of 
NICE surround its power as both an evaluation committee and an approval committee given the 
legal mandate of the NHS to fund recommended treatments. Given Americans' reluctance over 
the years to accept government guided health care, I believe an entity with greater independence 
from the federal government is more likely to garner public support. By funding it with both 
public and private money, undue influence from any funder (e.g. pharmaceutical or government) 
would be minimized. 
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Opening a national dialogue 
The Committee should also be charged with opening a national dialogue about the cost of 
care and reform efforts. I propose a town hall meeting approach in which Committee members, 
aided by a public relations and policy strategist, would bring together Americans to lay out why 
the high cost of medical care is a problem for them, and why they should support efforts to cut 
cost. Importantly, these meetings would need to stress the finite resources within health care, and 
that without change the cost of care has been shifting to the consumer. During the first year of 
this Committee, meetings should be held throughout the nation. Twice yearly meetings with 
rotating geographical sites should be held in following years to continue the dialogue and address 
concerns as they mount. Such meetings would also be a venue for the Committee to conduct 
research on the American public's political will regarding the use of cost in drug approval and 
reimbursement decisions, and what cut offs for cost -effectiveness would be acceptable to 
Americans. 
Related reforms within the FDA and CMS 
Though the idea that a committee that provides information about clinical and cost-
effectiveness will be enough to change practice is a nice ideal, the truth is that our system has 
grown so accustomed to accepting marginal benefits as improvements worthy of incorporation 
into practice that change is unlikely to occur without mandating the use of these data by agencies 
in charge of drug dispersion. Both CMS and the FDA must be made to incorporate cost into their 
decision-making about new technology, and must be forced to take a harder line against the 
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pharmaceutical industry-forcing it to foot the bill for ineffective drugs and making use of our 
vast market share to negotiate lower prices. 
Food and Drug Administration 
Currently, cost-effectiveness plays a minimal role in approval decisions made by the 
FDA: the case of the approval of erlotinib for use in metastatic pancreas cancer with a cost-
effectiveness ratio of $430,000 per quality adjusted life year is a clear example ofthis. The FDA 
does even less to limit the dispersion of new technologies, requiring only demonstration of 
safety, not efficacy, to approve new devices. The FDA, however, is the agency best positioned to 
incorporate cost into decision-making. I recommend that the FDA be mandated to review the 
proposed Effectiveness Committee's assessments of cost-effectiveness and comparative clinical 
effectiveness before approving a drug. I also believe that this should be the case for new devices 
as well. NICE has be criticized for slowing down drug dispersion through the UK, 75 a criticism 
the FDA also faces frequently. A conditional approval system, however, might circumvent this. 
By granting drugs approval through the traditional pathway while cost-effectiveness 
research is conducted by the committee, yet attaching a condition for post-marketing surveillance 
and cost-sharing, the FDA might be able decrease the burden imposed by marginally effective 
drugs on the US health care system. Drugs that prove ineffective in comparative effectiveness 
research or post-marketing surveillance would be denied. Drugs that demonstrate marginal 
benefit or a very high cost-effectiveness ratio would continue their conditional approval. Such 
conditional approval would allow drug companies to market their drug, and ease the clinical 
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trials process for development of the drug for other indications. Conditional approval, however, 
would allow Medicare to demand a cost -sharing proposal at the time of reimbursement decisions. 
Conditionally approved drugs could receive a form of fast-track re-review in the case of 
emerging evidence of effectiveness. 
Centers for Medicare and Medicaid Services 
CMS has always been the leader in reimbursement decisions in the complicated US 
health care market. As such, I believe changes within CMS to include cost as a consideration in 
reimbursement decisions would begin a national reform. This should occur in two ways. First, 
Medicare should consider cost in reimbursement decisions based on the recommendations of the 
Effectiveness Committee. While NICE has pre-existing cut-offs for what to recommend as cost-
effective, I believe Medicare should begin simply be reviewing cost-effectiveness research with 
each decision. Based on feedback from the Committee regarding what is acceptable to the public, 
cut-offs could be imposed in subsequent years. Secondly, CMS should use its power as a huge 
portion of the market to negotiate for lower drug costs. This would take two forms: for drugs 
receiving conditional approval by the FDA, CMS should demand drug companies foot part of the 
bill for patients in whom the drug proves ineffective; and, CMS should negotiate lower prices for 
all agents at the time of their reimbursement decisions. 
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Cetuximab for colorectal cancer, a prime example of needed reform 
The story of the ImClone drug cetuximab (Erbitux) is, I believe, an excellent example of 
how the proposed reforms could be made to decrease cost while still allowing new drugs to enter 
the marketplace. 
Cetuximab, a monoclonal antibody directed at the epidermal growth factor receptor, was 
approved in February of2004 for the use in EGFR expressing metastatic colorectal cancer 
refractory to irinotecan therapy. Approval was based on the results of a randomized phase II 
study comparing cetuximab alone to cetuximab and irinotecan. 78 This study showed tumor 
regression in 11% of patients treated with cetuximab and 23% of patients treated with cetuximab 
and irinotecan. Time until disease progression was also 2.6 months longer ( 4.1 months versus 1.5 
months) in the cetuximab/irinotecan arm. No survival difference was noted, though cross-over 
from the cetuximab arm to the cetuximab/irinotecan arm was permitted at the time of disease 
progressiOn. 
ImClone chose to market cetuximab at approximately $21,000 for 8 weeks of treatment, 
approximately $12,000 more per 8 weeks than the price chosen by Genetech for their 
blockbuster bevacizumab, also approved in February of 2004.45 An assessment by the NICE 
Centre for Health Technology was unable to calculate a cost-effectiveness ratio for cetuximab as 
there was no standard arm against which to compare it, however, their estimates suggested it 
would be well above £30,000. 12 Yet despite the cost, the very common acne-like rash that 
typically covers the face, and a substantial risk of anaphylaxis, cetuximab was rapidly 
incorporated into clinical practice as a second or third-line agent, largely because there are few 
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therapeutic options available to patients with metastatic colorectal cancer whose disease has 
progressed on chemotherapy. 
I believe that cetuximab would have been an optimal drug for conditional approval and 
some sort of cost-sharing program with CMS. Cetuximab was approved based on a 10% 
response rate and a 1.5 month time to progression-hardly a huge improvement in cancer 
outcomes despite few therapeutic options. However, it was clear from studies that the subgroup 
of patients who did respond seemed to have substantial benefit from the drug. Further research 
into who responds to cetuximab has uncovered that the approximately 30% of patients whose 
tumors harbor mutations in K-Ras (a molecule downstream of the action ofEGFR) essentially 
never respond to cetuximab, while those with normal K-Ras have a 40% chance of response-a 
figure four times that of the unselected group. 79· 80 These findings were just recently reported. 
Cooperative groups and the FDA are reviewing currently the use of cetuximab in ongoing and 
planned clinical trials. Yet, it is almost certain that approval of cetuximab will be narrowed to 
patients with a normal K-Ras only. Such an approval markedly enriches the population of 
responders, and thus clearly improves upon both the clinical and cost effectiveness of this agent. 
In retrospect, FDA approval of cetuximab in 2004 generated a huge amount of capital for 
ImClone at the expense of CMS and other payers, despite the fact that about a third of patients 
(the K-Ras mutant tumors) had no chance whatsoever of responding to therapy. Given the small 
benefit seen by patients in the registration trial, this drug may well have been singled out by the 
proposed new system for conditional FDA approval. Such conditional approval would have 
allowed ImClone to market cetuximab, continue to collect post-marketing data, and ease the 
regulations on cetuximab's inclusion in clinical trials under development. Conditional approval 
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would also have required that ImClone continue to foot part of the bill for a drug of minimal 
effectiveness, a strategy that would have saved CMS a huge amount of money. And, importantly, 
such conditional approval would not have compromised the research that has identified a group 
ofpatients-K-Ras wild-type-who is more likely to derive benefit from this drug. 
Summary 
The cost of all health care is on the rise, and the cost of cancer care leads the way. Attempts at 
cost containment have shifted the cost to consumers and health care professionals while failing to 
address to the true reason behind soaring prices. Our national desire to provide ideal care to each 
individual is truly noble, yet the finite resources available to finance this care do not allow ideal 
care to be available to all. Though Americans have been leaders in the fight to decrease suffering 
from cancer through emerging technology, we have failed in our ability to prevent growing 
inequity in care. As a nation we must face this reality together, and accept that in order to 
decrease the suffering caused by cancer for all Americans, we must personally be willing to 
sacrifice our ability to access every drug we might want. 
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